Abstract
Myostatin is a negative regulator of muscle mass. Important advances in our understanding of the complex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Here we present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adipose Tissue / metabolism
-
Animals
-
Humans
-
Muscles / metabolism
-
Muscular Dystrophies / metabolism
-
Myostatin
-
Rhabdomyosarcoma / metabolism
-
Rhabdomyosarcoma / pathology
-
Signal Transduction
-
Transforming Growth Factor beta / metabolism*
Substances
-
MSTN protein, human
-
Myostatin
-
Transforming Growth Factor beta